These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6845276)

  • 1. Monocyte tissue factor activity in anticoagulant-treated patients.
    Zacharski LR; Beck JR
    Thromb Res; 1983 Jan; 29(2):207-13. PubMed ID: 6845276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sodium warfarin on rabbit monocyte tissue factor expression.
    Edwards RL; Schreiber E; Brande W
    Thromb Res; 1986 Apr; 42(2):125-37. PubMed ID: 3715798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cyclosporine A on procoagulant activity in mononuclear blood cells and monocytes in vitro.
    Carlsen E; Mallet AC; Prydz H
    Clin Exp Immunol; 1985 May; 60(2):407-16. PubMed ID: 2408804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative elevation of human peripheral blood monocyte tissue factor coagulant activity.
    Blakowski SA; Zacharski LR; Beck JR
    J Lab Clin Med; 1986 Aug; 108(2):117-20. PubMed ID: 3734585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.
    Yacobi A; Udall JA; Levy G
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):552-8. PubMed ID: 1277711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
    Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
    Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ankaferd Blood Stopper and Celox on the tissue factor activities of warfarin-treated rats.
    Aktop S; Emekli-Alturfan E; Ozer C; Gonul O; Garip H; Yarat A; Goker K
    Clin Appl Thromb Hemost; 2014 Jan; 20(1):16-21. PubMed ID: 23702635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration.
    Saito M; Ajioka M; Iwao T; Suzuki T
    Biol Pharm Bull; 2018 Jul; 41(7):1014-1016. PubMed ID: 29760305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.
    Gitel SN; Wessler S
    J Lab Clin Med; 1979 Sep; 94(3):481-8. PubMed ID: 469382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects.
    Bruni F; Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Leo A; Auteri A
    Clin Exp Med; 2003 May; 3(1):45-53. PubMed ID: 12748879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring warfarin therapy in patients with lupus anticoagulants.
    Moll S; Ortel TL
    Ann Intern Med; 1997 Aug; 127(3):177-85. PubMed ID: 9245222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
    Zivelin A; Rao LV; Rapaport SI
    J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporine.
    Carlesen E; Prydz H
    Transplantation; 1987 Apr; 43(4):543-8. PubMed ID: 3576672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
    Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of the international normalised ratio in patients with liver disease.
    Deitcher SR
    Lancet; 2002 Jan; 359(9300):47-8. PubMed ID: 11809190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified anticoagulant therapy factor and international normalized ratio in patients in an unstable coagulation state with respect to warfarin therapy.
    Carroll WE; Jackson RD
    Res Commun Mol Pathol Pharmacol; 1999; 105(3):262-70. PubMed ID: 10954130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Measurement of Prothrombin Fragment 1+2 for the Assessment of Anticoagulant Activity in Patients Treated with Warfarin or Non-vitamin K Antagonist Oral Anticoagulant].
    Tomoda M; Yasaka M; Nakanishi Y; Takaguchi G; Nakamura A; Gotoh S; Kuwashiro T; Okada Y
    Brain Nerve; 2017 May; 69(5):571-576. PubMed ID: 28479535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients.
    Umeki S; Umeki Y
    Med Lab Sci; 1990 Apr; 47(2):103-7. PubMed ID: 2381266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic monitoring of warfarin: the appropriate response marker.
    Costa IM; Soares PJ; Afonso M; Ratado P; Lanaot JM; Falcão AC
    J Pharm Pharmacol; 2000 Nov; 52(11):1405-10. PubMed ID: 11186249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole potentiates warfarin-induced prothrombin time prolongation.
    Purkins L; Wood N; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):24-9. PubMed ID: 14616410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.